Precision oncology innovator SimBioSys and General Inception have joined forces in a strategic partnership aimed at revolutionizing cancer drug development.
In the fast-evolving landscape of clinical trials, technological advancements play a vital role in streamlining processes, enhancing efficiency, and ultimately improving patient outcomes.
ClinOne, a leading provider of clinical trial technology, has unveiled what it calls a major enhancement to its platform, offering customers far more control and flexibility.
An artificial intelligence (AI)-powered tool from UK-based Brainomix was one of only two products to be endorsed by health assessor the National Institute of Health and Care Excellence (NICE).
Clinical programmers can now further accelerate clinical study reporting, submission analysis and statistical modeling and more thanks to a new product in EDETEK’s informatics platform, Conform.
Clinical-stage precision oncology company, Repare Therapeutics Inc., has received a $40 million milestone payment from Roche after dosing the first patient in a clinical trial.
Andrew Mills, executive vice president of global commercial Lokavant and says the company can help businesses identify risk trends in trials much earlier than traditional methods.
Informatics software developer supporting R&D, ACD/Labs, has formed a collaboration with MilliporeSigma, the US and Canada Life Science business of Merck KGaA.
UK-based Lindus Health and US-based Thirty Madison today (December 14) announced they have completed the enrolment of a trial to assess their personalized dermatology telemedicine platform, Facet.
Element Biosciences, Inc., will share news of its sequencing methodology and host a workshop on higher accuracy sequencing for improved variant detection in Washington DC from today.
Slope, a site-first organization, ‘eliminating the chaos’ impacting clinical trials has joined CancerX as a founding member of The White House’s national Cancer Moonshot.
A study looking at the feasibility of using repeated sampling of validated digital measures at home, in patients with early-stage Alzheimer’s Disease (AD), has completed enrollment for a multi-site study.
The company announces plans to reorganize its business to focus on design-and-deployment engagements for on-site implementation of automated cloud labs.